Although an in vivo reduction in FM alleles in FXS patients seems unrealistic, detailed understanding of the FMR1 CGG repeat instability and consequent gene silencing may disclose new therapeutic approaches to treat Fragile X-related disorders. This evidence concerns the gene FMR1 and fragile X syndrome.